HGH — Research Dossier
Evidence grading
Structure
191 aa
Recombinant somatropin · ~22.1 kDa
FDA status
Approved
Deficiency & defined clinical indications
Anti-ageing use
Not approved
Risks outweigh benefits in healthy elderly
WADA status
Prohibited
Banned in sport — all routes and methods
Growth hormone is simultaneously one of the most rigorously studied hormones in medicine — approved for genuine deficiency states — and one of the most mythologised in anti-ageing culture, where the controlled evidence points the other way.
Recombinant human growth hormone (somatropin) reproduces the action of pituitary-derived GH, raising IGF-1 and influencing growth and body composition. It is FDA-approved for a range of defined indications, including paediatric and adult growth-hormone deficiency, Turner syndrome, Prader-Willi syndrome, children born small for gestational age, idiopathic short stature, SHOX deficiency, chronic renal insufficiency in children, and AIDS-associated wasting.
“The consistent conclusion is that GH is not recommended in healthy older adults because risks generally outweigh benefits.”
— Liu H et al., Ann Intern Med 2007 (systematic review)
Approved indications: what the evidence establishes
In genuine deficiency states, decades of controlled trials establish clear benefit, and somatropin has a well-described safety profile from use in millions of patients. The approved indications reflect this evidence base: paediatric and adult GHD, Turner syndrome, Prader-Willi syndrome, small for gestational age, idiopathic short stature, SHOX deficiency, chronic renal insufficiency (paediatric), and AIDS-associated wasting.
Healthy elderly and anti-ageing use
The 1990 Rudman study reported that six months of GH in men over 65 with low IGF-1 reduced adiposity and increased muscle mass, igniting interest in GH as an anti-ageing agent.
Subsequent, better-controlled work — including Blackman and colleagues (2002, JAMA) and a systematic review by Liu and colleagues (2007, Annals of Internal Medicine) — found only modest body-composition changes accompanied by frequent adverse effects: joint pain, oedema, carpal tunnel syndrome, and impaired glucose tolerance or diabetes.
The consistent conclusion across this literature is that GH is not recommended in healthy older adults because risks generally outweigh benefits. Ageing, anti-ageing, body-recomposition, and athletic performance are not approved uses of somatropin.
Safety profile and labelled risks
The labelled safety profile for somatropin includes:
- Neoplasms (including risk in patients with pre-existing malignancy or intracranial lesions)
- Glucose intolerance and new-onset type 2 diabetes
- Intracranial hypertension
- Increased mortality in acute critical illness (labelled contraindication)
- Fatalities in Prader-Willi syndrome patients with risk factors (respiratory impairment, obesity, sleep apnoea)
- Fluid retention, peripheral oedema, arthralgia, carpal tunnel syndrome
In endocrinologically normal people, adverse effects observed in controlled trials — oedema, arthralgia, carpal tunnel syndrome, impaired glucose metabolism — occurred at rates sufficient for reviewers to conclude that the risk-benefit balance does not favour use.
What this evidence is — and isn’t
These trials studied pharmaceutical-grade HGH administered under medical supervision in controlled settings. The figures summarised in this dossier describe that published science only.
They are not outcomes associated with research-grade material, and not results attributable to any use of the product sold in this catalogue. Nothing here is an endorsement, recommendation, or instruction for human use.
References
- 1
Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990.
- 2
Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002.
- 3
Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007.
- 4
U.S. Food and Drug Administration. Somatropin (rDNA origin) — Prescribing Information. FDA / Various manufacturers 2024.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.